Open-Label, Randomized Study to Estimate Safety, PK, and Efficacy of Oral SCY-078 vs. Standard-of-Care Following IV Echinocandin Therapy in the Treatment of Invasive Candidiasis in Hospitalized Nonneutropenic Adults

Trial Profile

Open-Label, Randomized Study to Estimate Safety, PK, and Efficacy of Oral SCY-078 vs. Standard-of-Care Following IV Echinocandin Therapy in the Treatment of Invasive Candidiasis in Hospitalized Nonneutropenic Adults

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs SCY 078 (Primary)
  • Indications Candidiasis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors SCYNEXIS
  • Most Recent Events

    • 24 May 2017 Data from this trial will be presented at the ASM Microbe 2017, according to a SCYNEXIS media release.
    • 25 Apr 2017 Results assessing safety, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 12 Apr 2017 According to a SCYNEXIS media release, data from this study will be presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top